Determination of Pregabalin in Human Plasma Using LC-MS-MS
Tóm tắt
A bioanalytical method has been developed and validated for determination of pregabalin in human plasma. The analytical method consists in the precipitation of plasma sample with trichloro acetic acid (20% v/v solution in water), followed by the determination of pregabalin by an LC-MS-MS method using gabapentin as internal standard. Separation was achieved on a Gemini C18 50 mm × 2.0 mm (3 μm) column with an isocratic mobile phase consisting of methanol–water (98:2, v/v) with 0.5% v/v formic acid. Protonated ions formed by a turbo ionspray in positive mode were used to detect analyte and internal standard. The MS-MS detection was by monitoring the fragmentation of 160.2→55.1 (m/z) for pregabalin and 172.2→67.1 (m/z) for gabapentin on a triple quadrupole mass spectrometer. The assay was calibrated over the range 0.1–15.0 μg mL−1 with correlation coefficient of 0.9998. Validation data showed intra-batch (n = 6) CV% ≤ 6.89 and RE (%) between −4.17 and +3.08 and inter-batch (n = 18) CV% < 9.09 and RE (%) between −3.0 and +10.00. Mean extraction recovery were 80.45–89.12% for three QC samples and 87.56% for IS. Plasma samples were stable for three freeze–thaw cycles, or 24 h ambient storage, or 1 and 3 months storage at −20 °C. Processed sample (ready for injection) were stable up to 72 h at autosampler (4 °C). This method has been used for analyzing plasma samples from a bioequivalence study with 18 volunteers.
Tài liệu tham khảo
Tassone DM, Boyce E, Guyer J, Nuzum D (2007) Clin Ther 29:26-48
Hamandi K, Sander JW (2006) Seizure 15:73-78
Kavoussi R (2006) Eur Neuropsychopharmacol 16:S128-S133
Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M (2005) Pain 115:254-263
Sharma U, Young J, LaMoreaux L (2005) Pain 6:S29
Arroyo S, Anhut H, Kugler AR, Lee CM, Knapp LE, Garofalo EA, Messmer S (2004) Epilepsia 45:20-27
Uthman BM, Lee CM, Spiegel K (2004) Epilepsia 45:1-393
Lydiard RB, Feltner DE, Robinson P, Liu-Dumaw M, Pande AC (2001) Eur Neuropsychopharmacol 11:S159-S160
Lauria HBA, Pohl RB (2003) Expert Opin Invest Drugs 12:663-672
Dooley DJ, Donovan CM, Meder WP, Whetzel SZ (2002) Synapse 45:171-190
Gee NS, Brown JP, Dissanayake VUK, Offord J, Thurlow R, Woodruff GN (1996) J Biol Chem 271:5768-5776
Fink K, Dooley DJ, Meder WP, Chauhan NS, Duffy S, Clusmann H, Gothert M (2002) Neuropharmacology 42:229-236
Dooley DJ, Donovan CM, Pugsley TA (2000) J Pharmacol Exp Ther 295:1086-1093
Dooley D J, Mieske CA, Borosky SA (2000) Neurosci Lett 280:107-110
Maneuf YP, Hughes J, McKnight AT (2001) Pain 93:191-196
Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T (2007) Epilepsy Res 73:1-52
Taylor CP, Angelotti T, Fauman E (2007) Epilepsy Res 73:137-150
Wesche D, Bockbrader H (2005) Pain 6:29
Stewart BH, Kugler AR, Thompson PR, Bockbrader HN (1993) Pharm Res 10:276-228
Turck D, Vollmer KO, Bockbrader H (1989) Eur J Clin Pharmacol 36:310
Vermeij TAC, Edelbroek PM (2004) J Chromatogr B 810:297-303
Berry D, Millington C (2005) Ther Drug Monit 27:451-456
Food and Drug Administration of the United States (2001) Guidance for industry-Bioanalytical Method Validation, U.S. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). http://www.fda.gov/cder/guidance/index.htm